Nurix Therapeutics, Inc. (NRIX)
After hours:
| Previous Close | 14.13 |
| Open | 14.05 |
| Bid | 13.66 x 100 |
| Ask | 13.78 x 500 |
| Day's Range | 13.52 - 14.42 |
| 52 Week Range | 4.22 - 18.12 |
| Volume | |
| Avg. Volume | 1,011,480 |
| Market Cap | 839.678M |
| Beta (5Y Monthly) | 2.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.66 |
| Earnings Date | Jul 11, 2024 - Jul 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.60 |
GlobeNewswireNurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. In addition, and in lieu of common stock, Nurix sold to certain investors pre-funded warrants to purchase 1,5
ZacksRoche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
- GlobeNewswire
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share. In addition, and in lieu of common stock, Nurix is offering to certain investors pre-funded warrants to purchase up to an aggregate of 1,500,100 shares of common stock at a purchase price of $14.999 per pre-funded warrant, which represents the per sha
